Moderna, Inc. (MRNA) Free cash flow 2016–2025
Moderna, Inc. (MRNA) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$2.1BFY2025 · since FY2016: $33.6M → -$2.1B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$2.1B | +49.1% |
| FY2024 | -$4.1B | -6.0% |
| FY2023 | -$3.8B | -183.5% |
| FY2022 | $4.6B | -65.6% |
| FY2021 | $13.3B | +580.8% |
| FY2020 | $2.0B | +499.0% |
| FY2019 | -$491.0M | -12.5% |
| FY2018 | -$436.6M | -12.0% |
| FY2017 | -$389.9M | -1260.7% |
| FY2016 | $33.6M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More MRNA financial trends
MRNA RevenueMRNA Net incomeMRNA Net marginMRNA Gross profitMRNA Gross marginMRNA Operating incomeMRNA Operating marginMRNA Operating cash flowMRNA Capital expendituresMRNA Return on equityMRNA Stock buybacksMRNA Dividends paidMRNA Total assetsMRNA Total liabilitiesMRNA Shareholders’ equityMRNA overview →